Verano Holdings (VRNO) Return on Capital Employed (2022 - 2026)
Verano Holdings' (VRNO) quarterly Return on Capital Employed came in at 6.79% in Q1 2026, up 671.0% year-on-year from 0.88% in Q1 2025, and down 7.3% on a QoQ basis from 6.32% in Q4 2025.
Verano Holdings (VRNO) Return on Capital Employed (2022 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 5 years of Return on Capital Employed data on file, last reported at 6.79% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 671.0% year-over-year to 6.79% in Q1 2026; TTM through Mar 2026 was 6.79%, a 671.0% increase from a year earlier, with the FY2025 full-year figure at 6.2%, up 594.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 6.79%, down from 6.32% in the prior quarter.
- Over the last five years, Return on Capital Employed for VRNO reached as high as 4.41% in Q4 2023 and fell as low as 14.16% in Q3 2025.
- Historically, Return on Capital Employed has averaged 4.96% across 5 years, with a median of 6.32% in 2025.
- Across the five-year window, Return on Capital Employed surged 1244 bps in 2023 and sank 1737 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 8.03% in 2022, then surged by 155 bps to 4.41% in 2023, then plunged by 376 bps to 12.15% in 2024, then soared by 48 bps to 6.32% in 2025, then fell by 7 bps to 6.79% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 6.79% in Q1 2026, 6.32% in Q4 2025, and 14.16% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | -6.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.79% |
| Dec 31, 2025 | -6.32% |
| Sep 30, 2025 | -14.16% |
| Jun 30, 2025 | -13.60% |
| Mar 31, 2025 | -13.50% |
| Dec 31, 2024 | -12.15% |
| Sep 30, 2024 | 2.55% |
| Jun 30, 2024 | 3.68% |
| Mar 31, 2024 | 3.87% |
| Dec 31, 2023 | 4.41% |
| Sep 30, 2023 | -5.13% |
| Jun 30, 2023 | -5.26% |
| Mar 31, 2023 | -6.86% |
| Dec 31, 2022 | -8.03% |
| Sep 30, 2022 | 2.95% |